Major PBMs Look Ahead to 2023 for Biosimilars Boom

With a raft of biosimilars coming to market starting in 2023, major PBMs are touting the pharmacy infrastructure and services that they say will position them to help customers take advantage of cost-saving opportunities in the coming years.

Speaking during recent conference calls to discuss first-quarter 2022 financial results, they also reported healthy client retention levels as PBMs move through the large-employer selling season.

“Our team is quite excited about and well positioned for the accelerating biosimilar trend that we see in front of us for the coming years,” Cigna CEO David Cordani said during a May 6 conference call to discuss first-quarter 2022 financial results, per a transcript from The Motley Fool.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

wall-street-sign-with-focus-on-sign-blurred-american-flag-background
February 10

Specialty Pharma Is Top of Mind for PBM Execs in Earnings Calls

READ MORE
wall-street-sign-with-focus-on-sign-blurred-american-flag-background
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
post-default-image
September 2

Humana/Anthem PBM Venture Could Attract More Blues Plans

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today